Background. Synchronous bilateral breast cancers frequently share the same estrogen receptor (ER) status, yet may differ in other histopathologic features. We sought to examine concordance rates of Oncotype DX recurrence score (RS) testing in women with synchronous bilateral ER-positive breast cancer.
Methods. Institutional databases were reviewed to identify patients with synchronous (within 6 months) bilateral primary invasive breast cancer and multiple RSs. RSs were stratified by risk group (RS \ 18, low; RS 18-30, intermediate; RS C 31, high) and considered discordant if they reflected different risk groups. Results. From 2005-2014, a total of 115 patients presented with synchronous bilateral invasive breast cancer; 43 (37 %) had two RSs available. Median patient age was 60 years (42-84), median tumor size was 1.2 cm (0.5-3.7), and all cases were HER2 negative and node negative. Of 86 RSs, 63 (73 %) were low risk, 20 (23 %) were intermediate risk, and 3 (3 %) were high risk. RSs were concordant in 29 (67 %) patients. Patients with concordant RSs were older (62 years vs. 56 years) and had median levels of progesterone receptor (PR) expression that were higher and more similar-80 and 85 % for bilateral cancers, respectively, compared with 55 and 75 % for bilateral cancers in discordant cases. Discordant RS led to a treatment change in 8/14 (57 %) cases. Conclusions. Among women with synchronous bilateral ER-positive HER2-negative breast cancer, RSs were concordant in 67 % of cases. Concordance rates may be higher in older women or among those with comparable levels of PR expression. These data suggest that testing of both tumors should be considered in patients who are candidates for adjuvant chemotherapy.
The 21-gene recurrence score (RS), Oncotype DX (Genomic Health, Redwood City, CA, USA), is widely used to assess risk of recurrence and benefit from chemotherapy in women with node-negative, estrogen receptor (ER)-positive breast cancer.
1,2 The 21-gene assay, which measures the relative levels of expression of genes associated with proliferation, invasion, HER2, and ER, provides a single RS which corresponds to a point estimate of the 10-year risk of distant recurrence with a 95 % confidence interval (CI). 3 The prognostic value of this assay has been demonstrated in clinical trials of both nodenegative and node-positive breast cancer, and numerous studies have shown that the Oncotype DX RS affects clinical decision making. [4] [5] [6] The incidence of synchronous bilateral invasive breast cancer is reported to range from 0.8-3.0 %, largely reflecting differing definitions used for synchronous diagnoses, with cutoffs ranging from within 3-12 months of initial diagnosis. 7, 8 Currently, there are no consistent evidence-based guidelines for the management of synchronous bilateral breast cancer (SBBC), and treatment decisions are often made based on the primary tumor with the most high-risk features. However, there is often considerable similarity in standard histopathologic features and hormone receptor status, making it difficult to differentiate how long-term prognosis is impacted by the presence of two primary tumors. The aim of this study was to determine the concordance rate for RS testing in women with synchronous bilateral primary breast cancer, and to identify clinical and pathologic features predictive of discordant RSs in this population. 
METHODS

RESULTS
From January 2005 to June 2014, a total of 115 patients presented with synchronous bilateral primary invasive breast cancer; 43 (37 %) of whom met eligibility criteria and had two RSs available. Patient and bilateral breast tumor characteristics are shown in Table 1 . Median patient age was 60 years (range 42-84 years) and median tumor size was 1.2 cm for both primary tumors, with minor differences in range (0.6-3.7 and 0.5-3.1, respectively). The majority of cases represented invasive ductal carcinomas, with a similar distribution of progesterone receptor (PR) positivity, nuclear grade, and histologic grade between bilateral breast primaries. All cases were node-negative; however, lymphovascular invasion (LVI) was identified in 7 % and 21 % of bilateral tumors, respectively. Among 86 primaries, 63 (73 %) were categorized as low risk, 20 (23 %) were categorized as intermediate risk, and 3 (4 %) were categorized as high risk by RS testing. No difference in median RS between the two groups of primary (bilateral) tumors was observed (Table 1) .
RSs were concordant in 29 patients (67 %). Table 2 illustrates the concordance rates for each risk group. There was no significant association between any clinical or histopathologic feature and the likelihood of having concordant or discordant RSs; however, patients with concordant RSs were older (62 years vs. 56 years) and had median levels of PR expression that were higher and more similar when compared with those with discordant scores (Table 3) .
RSs were ordered at the same time in 34 (79 %) patients and in a staged manner in the remaining 9 patients, with no Data are expressed as n (%) unless otherwise specified ER estrogen receptor, PR progesterone receptor, HER2 human epidermal growth factor receptor 2, IDC invasive ductal carcinoma, ILC invasive lobular carcinoma, LVI lymphovascular invasion a Tubular and mucinous carcinomas difference in rates of discordance between the two groups ( Table 3 ). The median time between RS testing for those performed in a staged manner was 31 days. Among the 14 patients with discordant scores, 3 had testing performed in a staged manner, and the second score reflected a higher risk group in all three cases, leading to a treatment change (recommendation for chemotherapy) in two of three cases. The time interval between testing in these three cases was 3 weeks, 3 weeks, and 10 weeks, respectively. Overall, treatment recommendations were affected by the higher of the two RSs in 8 of 14 (57 %) patients with discordant risk group scores (Table 4 ) or 18.6 % of the study population (8/43).
DISCUSSION
No consistent evidence-based guidelines are available for the management of SBBC, and treatment decisions are Intermediate (n = 13) 9 4
High (n = 3) 2 1 often made based on the primary tumor with the most highrisk features (i.e., hormone receptor status, HER2 status, size, grade, LVI, and others). In the setting of bilateral ERpositive, HER2-negative, node-negative breast cancer, this distinction may be difficult, as the tumors may appear quite similar by standard histopathologic criteria. There is now a large body of data supporting the use of the 21-gene RS to predict benefit from chemotherapy in the setting of unilateral disease; [1] [2] [3] [4] [5] [6] however, published data regarding the use of the RS in the setting of multiple synchronous breast cancers are limited to a single study by Toole et al., demonstrating that 2 of 4 (50 %) patients with multiple primary tumors in different breasts, and 4 of 18 (22 %) patients with multiple primaries in the same breast, had RS differences that led to changes in management. 9 In this study, we demonstrate that RSs were discordant in 33 % of women with ER-positive, HER2-negative, node-negative, synchronous bilateral invasive breast cancer, leading to a change in treatment in 57 % of these patients. To our knowledge, this is the only study to date examining concordance rates specifically in this population.
Since the first publication of a case series of SBBC by Kilgore in 1921, 10 there has been ongoing debate regarding the prognostic significance of bilateral disease. The concept of a time interval to distinguish between synchronous and metachronous bilateral breast cancer was first introduced by Haagensen in 1971. 11 He used 6 months as the cutoff for distinguishing these two categories; however, since then, various cutpoints have been used to define SBBC, ranging from 0-60 months, making it difficult to draw firm conclusions regarding the impact of bilateral disease on long-term outcomes. 12 Hartman et al. 13 analyzed incidence and mortality rates for bilateral breast cancer in a large nationwide cohort of 123,757 breast cancer patients in Sweden. Compared with women with unilateral disease, women with SBBC, defined as a contralateral diagnosis within 3 months, experienced inferior breast cancerspecific mortality at 10 years-45 % (95 % CI 41. and 33 % (95 % CI 32.8-33.5), respectively-and this difference was strongly influenced by age, whereby a diagnosis of SBBC under 50 years of age was associated with a 120 % higher mortality rate when compared with women with unilateral disease. For women with metachronous bilateral breast cancer, the mortality risk was largely dependent on the time interval between the two diagnoses, with those diagnosed more than 10 years later having similar 5-year breast cancer mortality to that of women of the same age with unilateral disease.
A large meta-analysis of 17 studies from 11 different countries, including 8050 SBBCs, defined as contralateral diagnosis within 6 months, also reported inferior outcomes for women with SBBC.
14 After adjusting for other known prognostic factors, the diagnosis of SBBC was associated with a pooled hazard ratio (HR) of 1.37 (95 % CI 1.24-1.50; p \ 0.0001) for breast cancer mortality compared with unilateral disease. However, among the four studies included in the meta-analysis that used a matched approach to compare prognosis between SBBC and unilateral breast cancer, no difference in disease-specific survival was observed, [15] [16] [17] [18] and in the sensitivity analysis of studies that included lymph node status as a covariate, there was also no difference in breast cancer mortality (pooled HR 1.18; 95 % CI 0.95-1.48).
14 The overall estimate of increased breast cancer mortality for patients with SBBC in this dataset does suggest, however, that there is room for improvement in determining appropriate adjuvant treatment for this patient subset.
In this study, we defined bilateral breast cancer as synchronous if the two diagnoses occurred within 6 months of each other; however, the majority of cases (39, 91 %) were diagnosed at the same time, and the remaining four (9 %) were diagnosed within a 3-month window. This observation likely reflects the increased use of breast magnetic resonance imaging (MRI) for extent of disease in patients with newly diagnosed breast cancer during the time period of this study. It is generally assumed that SBBC represents two clonally independent malignancies-a hypothesis that has been tested in clonality experiments by several different groups. [19] [20] [21] However, given the conflicting studies reporting outcome differences for women with unilateral versus bilateral breast cancer, it is plausible that a small proportion of these cases represent early metastatic events. [16] [17] [18] The ability to develop multiple tumors simultaneously may also be suggestive of an underlying genetic variation or susceptibility to malignancy, and some studies of patients with SBBC have suggested a relationship between family history and bilaterality; however, others have not confirmed this finding. [22] [23] [24] Multiple primary breast cancers share the same host, the same history in regard to metabolic changes, and the same exposure to external influences, yet there are limited data on how these shared characteristics impact concordance in regard to the molecular portrait of tumors. Buggi et al. examined 113 multiple (multicentric and multifocal) breast cancers of the same histologic subtype and found differences in grade (18.8 %), ER status (4.4 %), PR status (15.9 %), and HER2 status (9.7 %) in a minority of cases. 25 In an analysis of 12 patients with SBBC, Saad et al. reported similar histologic subtype in 58 % of cases, and similar ER, PR, and HER2 status in 67 % of cases. 26 Similar findings were reported by Hungness et al. and Coradini et al. 27, 28 Although we selected our patients to have bilateral ER-positive, HER2-negative, node-negative breast cancer, there was no significant difference in other traditional markers, such as histologic subtype, size, and grade when comparing the bilateral breast tumors, nor did we observe a significant difference in any of these parameters between tumors with concordant and discordant RSs. We did observe a trend for patients with concordant RS to be older (62 years of age vs. 56 years) and to have median levels of PR expression that were higher and more similar between the two primary tumors when compared with those with discordant scores; however, this finding awaits confirmation in a larger dataset (Table 3) .
Toole et al. also examined factors associated with discordant RSs. 9 Among 22 patients with either bilateral breast cancer (n = 4) or multiple primaries in the same breast (n = 18), eight patients had discordant RSs. In the Toole dataset, cases with discordant scores were more likely to differ in tumor histology (p = 0.05) and tumor grade (p = 0.04) than concordant cases. In patients with concordant scores, tumor histology and grade differed in 18.8 % and 6.3 % of cases, respectively, compared with 66.7 % and 50 % of cases for those with discordant scores. Although not statistically significant, tumors with different RSs were also more likely to differ in PR status (33.3 % vs. 18.8 %).
In our study, a change in chemotherapy recommendation based on the result of the second RS was made in 8 of 14 cases (57 %). In all cases, patients who would have not received chemotherapy based on one tumor score received chemotherapy due to a higher second score. In the cases with discordant RS and no treatment change (six patients), four patients received chemotherapy either due to one of the tumors having a high RS or physician/patient choice, and two patients whose bilateral tumors had low and intermediate RSs, respectively, received endocrine therapy alone. Changes in treatment recommendations based on discordant RS were also reported by Toole et al., where different scores led to a treatment change in 2 of 4 (50 %) patients with bilateral disease and 4 of 18 (22 %) patients with multiple tumors in the same breast.
CONCLUSIONS
Oncotype DX RSs were discordant in 33 % of women with ER-positive, HER2-negative, node-negative, synchronous bilateral invasive breast cancer, leading to a change in treatment in 57 % of these patients. To our knowledge, this is the only study to date examining concordance rates specifically in this population. Given our small sample size, we were unable to find significant clinical or pathologic predictors of discordant results; however, given the high rate of discordance, with the potential for a change in treatment recommendation and the controversy surrounding the prognostic impact of bilateral disease, these data suggest that testing of both tumors should be considered in patients with SBBC who are candidates for adjuvant chemotherapy.
